23 results about "Epidermal Dendritic Cells" patented technology

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

The application of the autologous dendritic cell in preparation of the medicine for treating the nerve injury erectile dysfunction can well promote recovery of the erectile function, perform staged reinfusion, induce immune regulation, repair nerve and blood vessel functions and improve a sex hormone regulation pathway. And the autologous dendritic cells are derived from a user, and have the advantages of safety, effectiveness and convenience in use. The combined immune cell therapy is obviously superior to a single treatment path in efficacy, is also more suitable for chronic, non-structural, subclinical and other ED people which are difficult to intervene by traditional methods, and has stronger individual adaptation ability and long-term controllability at the same time. Compared with a traditional scheme, the cell therapy targeting is better, and the treatment effect is faster.

The invention relates to migration of CCR7-mediated dendritic cell-derived exosomes and improvement of cardiac functions after myocardial infarction, in particular to a dendritic cell-derived exosome, CCR7 expression or activity in the dendritic cell is up-regulated, CCR7 overexpression can enhance migration of the dendritic cell-derived exosomes to the spleen, and CCR7 expression or activity of the dendritic cell-derived exosomes is up-regulated. And the CCR7 knockdown weakens the migration ability of the dendritic cell source exosome.

The invention belongs to the technical field of biological medicines, and particularly relates to application of crizotinib in induction of tolerant dendritic cells (tDCs). The invention provides an application of crizotinib in induction of tolerant dendritic cells. It is found that crizotinib can serve as an efficient inducer of tDCs, the activation state of DCs can be remarkably inhibited, the maturation function of DCs can be inhibited, the immune stimulation capacity of DCs can be reduced, then activation of T cells is inhibited, and therefore the crizotinib plays a role in treating immune diseases such as GVHD. In the invention, the inhibition of crizotinib on DCs comprises reduction of expression of maturation indexes CD80, CD40 and CD86. The crizotinib used in the invention is an ALK / ROS1 inhibitor approved by FDA and is mainly used for treating non-small cell lung cancer, the application of the crizotinib in immunotherapy is found, new use of old medicines is realized, and the crizotinib has great economic value.

This invention provides an activatable semiconductor polymer, its preparation method, and its applications. The activatable semiconductor polymer of this invention can efficiently accumulate at tumor sites. Due to the presence of electron-withdrawing groups on its side chains, the polymer's fluorescence is quenched. Upon response to tumor markers—biothiols, reactive oxygen species, and cathepsin B—the polymer's fluorescence recovers, enabling precise imaging and sonodynamic therapy at the tumor site. Simultaneously, the activatable semiconductor polymer of this invention can label immune cells (such as dendritic cells and macrophages) and track their metastasis from the tumor to the draining lymph nodes.

This invention belongs to the field of biomedical technology, specifically relating to the application of crizotinib in inducing tolerant dendritic cells (tDCs). This invention provides the application of crizotinib in inducing tolerant dendritic cells. This invention discovers that crizotinib can act as a highly effective inducer of tDCs, significantly inhibiting the activated state of DCs, suppressing their maturation function, reducing their immunostimulatory capacity, and thus inhibiting T cell activation, thereby exerting a therapeutic effect in immune diseases such as GVHD. The inhibitory effects of crizotinib on DCs in this invention include reducing the expression of maturation markers CD80, CD40, and CD86. The crizotinib used in this invention is an FDA-approved ALK / ROS1 inhibitor, primarily used for the treatment of non-small cell lung cancer. This invention discovers its application in immunotherapy, realizing the repurposing of an existing drug, and has significant economic value.

Provided is a novel gel-type microneedle patch for treating melanoma, which is loaded with dendritic cells (DC) and paclitaxel (PTX). The chemotherapeutic drug paclitaxel utilizes its own toxicity to

The application discloses a kind of biomimetic 3D printing hydrogel scaffold and its preparation method and application, belong to medical instrument technical field.The biomimetic 3D printing hydrogel scaffold includes 3D printing hydrogel scaffold and in 3D printing hydrogel scaffold surface imitating mussel catalytic coating;The biological ink of 3D printing hydrogel scaffold includes methacrylated gelatin, calcium ion pre-crosslinking sodium alginate, dendritic cell-derived exosome loaded with STING agonist and methacrylated modified osteogenic growth peptide;Imitate mussel catalytic coating is by polydopamine layer and the dopa-manganese metal polyphenol network nanoenzyme loaded on the surface of polydopamine layer jointly constitute.By the synergistic effect of each component, effectively solve the technical problem that existing scaffold lacks time sequence treatment mechanism, realize the dual effect of tumor removal and bone defect repair in bone metastasis tumor treatment.

The invention provides a rheumatoid arthritis biomarker as well as a screening method, application and a kit, and the rheumatoid arthritis biomarker is AXL + SIGLEC-6 + dendritic cells (AS DC for short). According to the invention, AS DC can be used as a specific marker for evaluating the disease activity of RA for the first time, and the disease activity of RA can be effectively measured.

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

The invention discloses application of kinsenoside in preparation of drugs for inhibiting metabolic inflammation and improving obesity, kinsenoside regulates and controls an immune system, induces dendritic cells to express immunosuppressive molecules PD-L1 and inhibits costimulatory molecules CD86, so that tolerance of kinsenoside is maintained. The effect further inhibits the activation and infiltration of downstream T cells, and finally reduces the recruitment and activation of macrophages in fat and liver tissues, and breaks the vicious circle of metabolic inflammation. Animal experiments show that the kinsenoside can effectively inhibit weight gain induced by high fat diet and improve abnormal glucose tolerance, insulin resistance, liver lipid deposition and dyslipidemia. The invention discloses the effect of kinsenoside in treating obesity and related complications thereof through a targeted immune metabolic axis for the first time, and provides a new strategy and a candidate compound for developing novel and safe anti-obesity drugs.

Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved by administering a composition comprising a fms related tyrosine kinase 3 ligand (Flt3L) polypeptide to the subject.

To provide a dendritic cell generating apparatus and method.SOLUTION: A cell culture cartridge comprises a plurality of zones geometrically configured to provide a symmetrical fluid flow with each of the plurality of zones to avoid dead areas in a flow within each of the plurality of zones. In certain embodiments, at least eight inlets are provided, with an inlet positioned at each corner of the cell culture cartridge. In certain embodiments, a shared outlet is positioned on a top surface of the cell culture cartridge. The present invention provides an optimal and further efficient approach to automated generation of dendritic cells (DCs).SELECTED DRAWING: None

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, such as lipid nanoparticles (LNPs), for targeted delivery to tissues or cell types. The compounds and formulations provided herein are designed to have a targeting moiety configured to provide selective delivery characteristics for the formulation, and a lipid tail for incorporation into a bilayer membrane of the formed lipid nanoparticles.

The subject invention relates to a novel compound and method for treating cancer in a subject using photodynamic therapy (PDT). The novel compound comprises zinc(II) phthalocyanine substituted with two or four nitric oxide (NO)-releasing moieties that release NO upon interaction with the intracellular glutathione, which reduces the cellular oxygen consumption rate, thus relieving the hypoxic status of cancer cells. Upon light irradiation, the novel compound generates reactive oxygen species (ROS), induces cytotoxicity under a hypoxic condition, overcoming the oxygen-dependent nature of PDT, and elicits the release of damage-associated molecular patterns, inducing the maturation of dendritic cells and triggering an antitumor immune response.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

The invention belongs to the technical field of preparation of immune activators, and particularly relates to a preparation method of an autoimmune activator. The invention provides a preparation method of an autoimmune activator, which comprises the following steps: separating an albuginea layer from peripheral blood, then respectively preparing an autoimmune exosome and an autovariant cell immune antigen through the steps of resuspension counting, water bath heating, programmed cooling, unfreezing centrifugation and the like, and mixing, freezing and drying to obtain the autoimmune activator. The technical scheme is simple and convenient, the obtained autoimmune activator is high in activity, and after subcutaneous injection, the autoimmune activator can effectively activate subcutaneous Langerhans cells, dendritic cells and the like, enhance the recognition ability of DC cells on antigens, induce Langerhans cells / DC cells to activate Th cells, enhance the effect of effector T cells and remove in-vivo variant cells, so that the autoimmune activator has a good immunogenicity. Therefore, autoimmune diseases or other health problems with immune imbalance states are improved, and the composition is safe and free of side effects.

The invention relates to the technical field of cellular immunotherapy, in particular to application of anacridine in preparation of a dendritic cell (DCs) immunologic adjuvant. The invention provides an application of anacridine in preparation of a dendritic cell immunologic adjuvant. The invention finds that the anacridine can promote the maturing and migration functions of the DCs, and the migration ability of the DCs is remarkably improved. The activation aspect of the anacridine on the DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86 and expression of a migration index CCR7. The anacridine used in the invention is a chemotherapeutic drug approved by FDA for clinical treatment of acute leukemia and malignant lymphoma, the application of the anacridine in immunotherapy is found, new use of old drugs is realized, and the anacridine has significant economic value.

The application provides a fluorine-containing polymer for spleen-selective nucleic acid delivery, a polymer-lipid hybrid nanoparticle and a preparation method and application thereof. The preparation method of the fluorine-containing polymer for spleen-selective nucleic acid delivery comprises the following steps: preparing the fluorine-containing polymer through ring-opening addition reaction of alkylene oxide, fluorine-substituted alkylene oxide and polyethylene imine. The preparation method of the fluorine-containing polymer is simple, the conditions are mild, and the yield of the finished product is high; the obtained fluorine-containing polymer is used for preparing the polymer-lipid hybrid nanoparticle, nucleic acid can be specifically delivered to the spleen and play a role, the polymer-lipid hybrid nanoparticle has a good transfection effect on spleen dendritic cells, and has good biological safety.